Impact of thyroid disease in patients with atrial fibrillation: Analysis from the JoFib registry

• DOI: 10.1016/j.amsu.2022.103325
• Publication Date: 2022-01-30T00:31:28Z
• Authors: Hanna Al-Makhamreh; Abdallah Al-Ani; Dana Alkhulaifat; Liza Shaban; Neveen Salah; Rusul Almarayaty; Yazan Al-Huneidy; Ayman Hammoudeh
• Keywords: Dyslipidemia; Thyroid disease; Stroke

Thyroid disease is a well-established risk factor for atrial fibrillation (AF). However, only handful of studies examined its impact on treatment. This study aims to report the prevalence rate thyroid in patients with AF and demonstrate effect treatment.We retrospectively analyzed Jordanian Atrial Fibrillation Study (JoFib). Among Jordan Palestine, were evaluated their sociodemographic, clinical, pharmacological characteristics.A total 2000 (53.3% males, mean age 67.6 ± 13.1 years) enrolled JoFib registry from May 2019 November 2020. was present 210 (10.5%) patients. Hypertension, diabetes mellitus, dyslipidemia most common comorbidities among history (75.2%, 51.0%, 45.7%, respectively). Diabetes mellitus (p = .04), pulmonary hypertension .01), chronic kidney .01) significantly higher this particular subgroup. Patients demonstrated usage anticoagulants .02).Despite having similar stroke bleeding risks, meaningful differences baseline characteristics. Prospective are required assess influence hormone fluctuations progression AF.